• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Repligen Corp (NQ: RGEN )

    140.70 -3.18 (-2.21%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Repligen Corp

    < Previous 1 2 3 4 5 6 Next >
    Repligen Joins Elite List Of Stocks With 95-Plus Composite Rating
    The new score means Repligen is now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria. 
    Via Investor's Business Daily
    Exposures COVID-19
    Dow Jones Hits High As Metals, Miners, Fertilizers Thrive, But Growth Stocks Slump; Jobs Report Stunningly Weak
    The Dow hit highs but growth stocks slumped, despite a Friday bounce on weak jobs gains. Miners, metals, fertilizers thrived. 
    Via Investor's Business Daily
    Topics Economy Intellectual Property Stocks
    Exposures COVID-19 Intellectual Property Interest Rates
    Repligen Corp (RGEN) Q1 2021 Earnings Call Transcript
    RGEN earnings call for the period ending March 31, 2021. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
    Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
    Via Benzinga
    Exposures Product Safety
    Repligen Earnings Double As Sales Growth Accelerates; RGEN Stock Nears Buy Point
    Repligen earnings shot up 113% in Q1 with sales growth accelerating to 88%. The biotech raised full-year guidance. RGEN stock rose, nearing a buy point. 
    Via Investor's Business Daily
    Repligen: Q1 Earnings Insights
    Shares of Repligen (NASDAQ:RGEN) moved higher by 7.5% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 112.50% over... 
    Via Benzinga
    The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)... 
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Gainers BioLine Rx (NASDAQ:BLRX) shares moved upwards by 65.2% to $5.27 during Tuesday's pre-market session. The market value of their outstanding shares is at $226.7... 
    Via Benzinga
    Repligen Stock Gets Relative Strength Rating Upgrade With Earnings Due
    A Relative Strength Rating upgrade for Repligen shows improving technical performance. Will it continue? 
    Via Investor's Business Daily
    Medical Device Maker Quanterix Sees Relative Strength Rating Rise To 86
    On Tuesday, Quanterix stock hit an important technical milestone, with its Relative Strength (RS) Rating rising into to 86, up from 80 the day before. 
    Via Investor's Business Daily
    Align Technology Nears Buy Point With Earnings Due
    Align Technology is near a possible buy zone ahead of its next quarterly earnings report, expected on or around April 28. 
    Via Investor's Business Daily
    Earnings Scheduled For May 4, 2021
    Companies Reporting Before The Bell • Lancaster Colony (NASDAQ:LANC) is likely to report quarterly earnings at $1.24 per share on revenue of $340.02 million. •... 
    Via Benzinga
    Cancer Therapy Novocure Stock Still On A High As It Clears Technical Benchmark
    Cancer therapy Novocure stock had its Relative Strength (RS) Rating upgraded from 90 to 93 Wednesday. It's also an IBD 50 member. 
    Via Investor's Business Daily
    Cancer Therapy Novocure Stock Flashes Renewed Technical Strength
    Novocure stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 67 to 92. 
    Via Investor's Business Daily
    10 Biggest Price Target Changes For Monday
    Canaccord Genuity raised the price target on Tesla, Inc. (NASDAQ: TSLA) from $419 to $1071. Tesla shares rose 1.5% to $687.13 in pre-market trading. Keybanc lowered the price... 
    Via Benzinga
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.